Drug Trial Radar · NCT02128958
Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
Last checked: Nov 19, 2026Latest source record: Oct 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Sep 2014
Primary completion
Nov 27, 2017
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Can-Fite BioPharmaIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.
Conditions
- Hepatocellular Carcinoma
Interventions
CF102Drug
orally q12h
PlaceboDrug
orally q12 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Overall SurvivalTime frame: From date of first treatment (Cycle 1 Day 1) until date of death from any cause, assessed up to 12 months
Locations
21 sites in 5 countries. Site status is shown where the registry gives one.
University of Colorado Cancer Center
Aurora, Colorado
Simmons Cancer Center
Dallas, Texas
Complex Oncology Center - Plovdiv
Plovdiv, Bulgaria
Multiprofile Hospital for Active Treatment Central Onco Hospita
Plovdiv, Bulgaria
Multiprofile Hospital for Active Treatment "Tokuda Hospital Sofia" AD
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment for women's health - Nadezhda
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment Serdica
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment "Sveta Marina" EAD
Varna, Bulgaria
Rabin Medical Center
Petah Tikva, Israel
Institutul Clinic Fundeni - Sectia Oncologie Medicala
Bucharest, Romania
Clinica Bendis - Oncologie Medicala
Cluj-Napoca, Romania
Centrul de Oncologie ONCOLAB
Craiova, Romania
Institutul Regional de Oncologie Iasi - Sectia Oncologie Medicala
Iași, Romania
Spitalul Pelican Impex SRL- Sectia Oncologie Medicala
Oradea, Romania
SC DACMED SRL - Oncologie
Ploieşti, Romania
Spitalului Clinic Judetean de Urgenta - Sectia Oncologie Medicala
Sibiu, Romania
Spitalul Judetean de Urgenta "Sf. Ioan Cel Nou" - sectia Oncologie Medicala
Suceava, Romania
Vojnomedicinska Akademija Beograd
Belgrade, Serbia
Institut za Onkologiju Vojvodine
Kamenitz, Serbia
Zdravstveni Centar Kladovo Služba Onkologije
Kladovo, Serbia
Klinički Centar Niš Klinika za Onkologiju
Niš, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.